Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Read More
Interim results presented by UNC’s Joseph Muenzer, MD, PhD, provide preliminary evidence that in vivo genome editing occurred in a clinical trial testing a treatment for Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome.
Read More
Authorities in China say experiments which led to the birth of the world’s first gene-edited babies broke the country’s laws, state-run Xinhua news reported Monday.
Read More
Under the terms of the agreement, Locus will receive $20 million in initial payments and is eligible to receive up to $798 million in potential future development and commercial milestone payments and royalties on any product sales. Here’s a look at the deal and CRISPR science.
Read More
Sapan Shah, a 20-year life science industry veteran, is the new chief executive officer at Durham-based startup StrideBio.
Read More
A new licensing deal means $20 million up front and as much as $798 million in potential future payments for RTP-based Locus Biosciences.
Read More
A number of companies today are using CRISPR in research platforms with the goal of harnessing the power to rewrite DNA.
Read More
The World Health Organization is creating a working group to study gene editing and the complex ethical, social and safety issues the procedure raises.
Read More
